Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q4 2013 · 10-K
Revenue$21.48M$21.48M+1,423.5% vs Q4 2012 Net Income-$2.93M-$2.93MN/M vs Q4 2012 EPS Diluted-$0.03-$0.03N/M vs Q4 2012 Operating Income-$3,447,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,492,000N/M Margins · derivedOperating margin-16.0%+1187.9 pt vs Q4 2012
Net margin-13.7%+1221.4 pt vs Q4 2012
ended Dec 31, 2014 · filed Mar 12, 2015 · 71 d after period end